荣丰控股集团股份有限公司 2023 年第三季度报告 证券代码：000668 证券简称：荣丰控股 公告编号：2023-058 荣丰控股集团股份有限公司 2023 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述 或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准 确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 18,832,602.86 | -90.06% | 40,497,532.72 | -91.93% | | 归 ...

证券代码：000668 证券简称：荣丰控股 公告编号：2023-060 荣丰控股集团股份有限公司 第十届监事会第十四次会议决议公告 经审议，监事会认为，董事会编制和审议公司 2023 年第三季度报告的程序 符合法律、行政法规及《公司章程》的规定，报告内容真实、准确、完整地反映 了公司的实际经营情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《荣丰控股集团股份有限公司 2023 年第三季度报告》（公告编号：2023-058）。 三、备查文件 1. 公司第十届监事会第十四次会议决议。 特此公告 荣丰控股集团股份有限公司监事会 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 荣丰控股集团股份有限公司（以下简称"公司"）第十届监事会第十四次会 议于 2023 年 10 月 27 日上午以通讯方式召开，会议通知已于 2023 年 10 月 24 日以电子邮件方式发出。本次监事会应到监事 3 人，实到监事 3 人。会议由监事 会主席贾明辉女士主持，公司董 ...

荣丰控股集团股份有限公司（以下简称"公司"）董事会沉痛宣告，公司第 五、六、七届独立董事苗立胜先生因病医治无效，于 2023 年 10 月 27 日在北京 不幸逝世，享年 77 岁。 公司董事、监事、高级管理人员及全体员工对苗立胜先生的逝世表示沉痛哀 悼，并向他的夫人刘永生女士及其他亲属致以深切慰问。 特此公告 荣丰控股集团股份有限公司董事会 二〇二三年十月二十七日 证券代码：000668 证券简称：荣丰控股 公告编号：2023-061 荣丰控股集团股份有限公司 关于原独立董事逝世的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

第十届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：000668 证券简称：荣丰控股 公告编号：2023-059 荣丰控股集团股份有限公司 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《荣丰控股集团股份有限公司 2023 年第三季度报告》（公告编号：2023-058）。 三、备查文件 1. 公司第十届董事会第二十六次会议决议。 特此公告 荣丰控股集团股份有限公司董事会 二〇二三年十月二十七日 荣丰控股集团股份有限公司（以下简称"公司"）第十届董事会第二十六次 会议于 2023 年 10 月 27 日上午以通讯方式召开，会议通知已于 2023 年 10 月 24 日以电子邮件方式发出。本次董事会应到董事 7 人，实到董事 7 人，会议由董事 长王征先生主持，公司监事、高级管理人员列席了本次会议，会议的召开符合《公 司法》等法律法规及《公司章程》的规定。 二、董事会会议审议情况 1.7 票同意，0 票反对，0 票弃权，审议通过《2023 年第三季度报告 ...

证券代码：000668 证券简称：荣丰控股 公告编号：2023-057 荣丰控股集团股份有限公司 关于就撤销表决权委托事项提起诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.案件所处的诉讼阶段：已立案尚未开庭 2.上市公司所处的当事人地位：原告 一、本次诉讼事项受理的基本情况 荣丰控股集团股份有限公司（以下简称"公司"）于 2023 年 9 月 5 日向上海 市浦东新区人民法院提交民事起诉状，要求长沙文超管理企业（有限合伙）、新 余纳鼎管理咨询合伙企业（有限合伙）支付撤销表决权委托违约金 2,500 万元， 上海市浦东新区人民法院于 2023 年 10 月 24 日立案，案号为（2023）沪 0115 民初 112851 号。 二、有关本案的基本情况 （一）原告： 荣丰控股集团股份有限公司 （二）被告： 被告一：长沙文超管理企业（有限合伙） 被告二：新余纳鼎管理咨询合伙企业（有限合伙） （三）事实与理由： 3.涉案的金额：2,500 万元 4.对上市公司损益产生的影响：本案尚未开庭审理，目前尚无法判断对公司 本期利润或期后利润的影响 ...

证券代码：000668 证券简称：荣丰控股 公告编号：2023-056 荣丰控股集团股份有限公司 关于就业绩补偿事项提起诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.案件所处的诉讼阶段：已立案尚未开庭 2.上市公司所处的当事人地位：原告 3.涉案的金额：业绩补偿款 19,325,737.84 元及逾期付款违约金 4.对上市公司损益产生的影响：本案尚未开庭审理，目前尚无法判断对公司 本期利润或期后利润的影响。公司将积极跟进该诉讼案件的进展情况，并及时履 行信息披露义务，敬请投资者注意投资风险。 一、本次诉讼事项受理的基本情况 荣丰控股集团股份有限公司（以下简称"公司"）于 2023 年 9 月 5 日向上海 市浦东新区人民法院提交民事起诉状，要求宁湧超履行业绩承诺补偿义务，上海 市浦东新区人民法院于 2023 年 10 月 23 日立案，案号为（2023）沪 0115 民初 112460 号。 二、有关本案的基本情况 新余纳鼎管理咨询合伙企业（有限合伙）（以下简称"新余纳鼎"）、盛世达投资 有限公司（以下简称"盛世达"）、农金高投（ ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥21,664,929.86, a decrease of 93.07% compared to ¥312,499,586.98 in the same period last year[20]. - The net profit attributable to shareholders was a loss of ¥29,206,520.94, worsening by 105.27% from a loss of ¥14,228,206.40 in the previous year[20]. - The basic and diluted earnings per share were both -¥0.20, reflecting a 100% decline compared to -¥0.10 in the same period last year[20]. - The company reported a significant decrease in sales revenue, with cash received from sales of goods and services at 24,766,507.55 yuan, down from 366,817,288.39 yuan in the first half of 2022[129]. - The total profit for the first half of 2023 was -29,852,077.84 yuan, down from 17,761,641.93 yuan in the previous year, reflecting a negative performance trend[123]. Cash Flow - The net cash flow from operating activities improved to -¥38,425,423.99, a 50.21% increase compared to -¥77,170,579.72 in the same period last year[20]. - The cash flow from operating activities was primarily affected by a decrease in cash received from operating activities, which totaled 5,370,076.81 RMB[134]. - The company reported a significant decrease in cash paid for operating activities, which was 12,388,204.06 RMB compared to 83,134,436.13 RMB in the previous year[134]. - Total cash inflow from investment activities was 25,544,885.29 RMB, while cash outflow was 22,298.00 RMB, resulting in a net cash flow of 25,522,587.29 RMB[134]. - Cash inflow from financing activities amounted to 57,190,000.00 RMB, with cash outflow totaling 41,666,522.96 RMB, leading to a net cash flow of 15,523,477.04 RMB[134]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,133,313,925.43, down 8.35% from ¥2,327,735,447.65 at the end of the previous year[20]. - The total liabilities decreased to CNY 860,131,320.36 as of June 30, 2023, from CNY 1,014,684,981.23 at the start of the year, a decline of about 15.19%[117]. - The total equity attributable to shareholders was CNY 1,189,038,792.42 as of June 30, 2023, down from CNY 1,218,245,313.36 at the beginning of the year, representing a decrease of approximately 2.40%[117]. - The company's long-term equity investments were valued at CNY 279,005,570.75 as of June 30, 2023[116]. - The total current liabilities amounted to CNY 859,786,169.83, down from CNY 1,014,361,053.94 at the beginning of the year, indicating a decrease of approximately 15.23%[117]. Inventory and Receivables - Inventory increased to ¥1,101,793,095.06, which is 51.65% of total assets, up by 2.07% compared to the previous year[40]. - The company reported a significant decrease in accounts receivable, which fell to ¥2,861,569.22, representing only 0.13% of total assets, down by 0.28%[40]. - Accounts receivable decreased significantly from ¥9,461,082.07 to ¥2,861,569.22, a reduction of about 70%[115]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has not disclosed any new product developments or market expansion strategies in the report[27]. - The company plans to leverage favorable policies to expand financing channels and reduce costs[56]. - The company aims to identify high-quality assets with sustainable growth potential to continue its business transformation and enhance sustainable development capabilities[58]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[136]. Risk Management - The company faced significant risks as outlined in the report, which investors should be aware of[4]. - The company is focusing on enhancing its risk management strategies to mitigate potential market fluctuations[136]. - The company has implemented a strategy to provide guarantees for homebuyers' bank mortgage loans[35]. Shareholder Information - The total number of shares outstanding is 146,841,890, with 99.90% being unrestricted shares[100]. - The largest shareholder, Shengshida Investment Co., Ltd., holds 40.81% of the shares, totaling 59,926,083 shares[103]. - The total number of common shareholders at the end of the reporting period is 8,158[102]. Financial Reporting - The semi-annual financial report has not been audited[76]. - The financial report for the first half of 2023 has not been audited[113]. - The company's financial statements are prepared based on the assumption of going concern, with no significant doubts about its ability to continue operations[154]. - The financial statements of the company comply with the requirements of the accounting standards and reflect the financial position, operating results, and cash flows accurately[156].

荣丰控股集团股份有限公司 2022 年度业绩说明会投资者关系活动记录表 荣丰控股集团股份有限公司 投资者关系活动记录表 编号：2023-001 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | | 董事长 王征先生 | | 活动参与人 | 副董事长、总裁 王焕新女士 | | 员 | 董事会秘书 谢高先生 | | | 财务总监 吴庆女士 | | 时间 | 2023 年 5 月 24 日 15:00-17:00 | | 地点 | 互动易云访谈平台（http://irm.cninfo.com.cn） | | 形式 | 网络在线文字交流形式 | | | 1、从公司卖出医疗资产看，王总还是真心为公司好的，希望公司 | | | 在王总带领下能够走出亏损，走上成功。 | | | 答：投资者您好！感谢理解，控股股东将一如既往地支持上市公司 | | | 发展。 | | 交流内容及 | | | 具体问答记 | 2、很多房地产股票都面临退市， ...

证券代码：000668 证券简称：荣丰控股 公告编号：2023-049 关于举行 2022 年度网上业绩说明会的公告 二〇二三年五月十七日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 荣丰控股集团股份有限公司（以下简称"公司"）2022年年度报告已于2023 年4月28日在巨潮资讯网（http://www.cninfo.com.cn）上披露，为便于广大投 资者进一步了解公司2022年度业绩和经营情况，公司定于2023年5月24日（周三） 15:00-17:00在深圳证券交易所"互动易"平台举办2022年度业绩说明会，本次 年度业绩说明会将采用网络远程的方式举行，投资者可登录"互动易"网站 （http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次年度业绩说明会。 特此公告 荣丰控股集团股份有限公司董事会 荣丰控股集团股份有限公司 出席本次说明会的人员有：公司董事长王征先生、副董事长兼总裁王焕新女 士、财务总监吴庆女士、董事会秘书谢高先生。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，以广 ...

Financial Performance - Rongfeng Holding Group reported a significant increase in revenue, reaching 1.2 billion RMB, representing a 15% growth year-over-year[18]. - The company's operating revenue for 2022 was ¥638,630,183.30, representing a 153.16% increase compared to ¥252,258,986.94 in 2021[26]. - The company reported a net profit attributable to shareholders of CNY -37.93 million, indicating a decline in profitability[1]. - The company reported a significant increase in revenue after deducting non-recurring income, with a total of ¥629,541,754.31 in 2022 compared to ¥151,761,002.33 in 2021[28]. - The company experienced a net loss in each quarter of 2022, with the fourth quarter loss amounting to -¥10,146,232.59[32]. - The company reported a government subsidy of 24.84 million CNY, which is closely related to normal business operations[37]. - The company reported a positive net profit for the reporting period, with the parent company's distributable profit being positive, but no cash dividend distribution plan was proposed[146]. Market Strategy and Expansion - The company plans to expand its market presence in the medical device sector, aiming for a 20% increase in market share by 2025[24]. - Future guidance suggests an expected revenue growth of 10% for the next fiscal year, driven by new product launches[18]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[123]. - A strategic acquisition of a tech startup was announced, expected to enhance the company's product offerings and increase market competitiveness[123]. - The company is actively seeking high-quality assets to continue its business transformation towards sustainable growth capabilities[93]. Research and Development - The company has allocated 200 million RMB for research and development of new technologies in the healthcare sector[24]. - Research and development investment increased by 30%, totaling $150 million, aimed at advancing new technologies[123]. Operational Efficiency - The company reported a net profit margin of 12%, indicating improved operational efficiency compared to the previous year[18]. - The average price reduction for orthopedic spinal implants under the national centralized procurement policy reached 84%, significantly impacting the medical device distribution business[42]. - The gross margin for property management and leasing was 31.45%, despite a year-on-year revenue decline of 17.25%[53]. Financial Challenges - The net cash flow from operating activities decreased by 175.90% to -86,637,343.25 CNY compared to the previous year[68]. - The company faced a debt restructuring loss of 876.60 thousand CNY during the reporting period[37]. - The company has lost effective control over its subsidiary, Weiyu Medical, following the termination of voting rights delegation agreements[150]. - The company reported a significant decline in revenue due to the loss of control over Anhui Weiyu Medical Technology Co., which is expected to lead to a substantial decrease in future revenue scale[87]. Corporate Governance - The company adheres to the governance requirements set by the China Securities Regulatory Commission and has improved its management systems and governance structure[104]. - The board of directors consists of 7 members, including 3 independent directors, and has established specialized committees to oversee various functions[106]. - The company maintains independence from its controlling shareholder in terms of business, personnel, assets, institutions, and finance, ensuring a complete and independent operation[107]. Investor Relations - The company is actively engaging with investors about its operational status and the progress of various transactions, including the acquisition of Hunan Weiyu[100]. - There have been inquiries regarding the company's annual report and the timeline for its disclosure, indicating investor interest in financial performance[99]. - The company is planning to disclose its semi-annual performance forecast, which is anticipated by investors[100]. Employee Management - The total remuneration for the 13 current directors, supervisors, and senior management in the company amounted to 5.5198 million yuan[127]. - The employee training plan includes at least 12 general training sessions and 6 professional training sessions throughout the year, aiming to enhance employee skills and overall company performance[145]. - The company has a structured remuneration decision-making process for its senior management, which is approved by the board of directors[127]. Social Responsibility - The company emphasizes the importance of social responsibility while pursuing economic benefits, ensuring fair treatment of stakeholders[160]. - The company has implemented measures to enhance employee welfare, including training and benefits, to improve job satisfaction and productivity[160]. Performance Commitments - The company has performance commitments for the years 2021, 2022, and 2023, with net profit targets of RMB 117.1243 million, RMB 102 million, and RMB 123 million respectively[165]. - The company is currently fulfilling its performance commitments and has not encountered any overdue obligations[165]. - The performance compensation arrangement includes a provision for impairment testing, where the compensation amount is capped at the total transaction price of the transferred equity[165].